Next Article in Journal
A Reproducible Deep-Learning-Based Computer-Aided Diagnosis Tool for Frontotemporal Dementia Using MONAI and Clinica Frameworks
Previous Article in Journal
Synthetic Genetic Elements, Devices, and Systems
Previous Article in Special Issue
Current Status of Biparametric MRI in Prostate Cancer Diagnosis: Literature Analysis
 
 
Systematic Review

Quality of Multicenter Studies Using MRI Radiomics for Diagnosing Clinically Significant Prostate Cancer: A Systematic Review

Medical Imaging Center, Departments of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Vittoria Rago
Life 2022, 12(7), 946; https://doi.org/10.3390/life12070946
Received: 27 May 2022 / Revised: 20 June 2022 / Accepted: 21 June 2022 / Published: 23 June 2022
(This article belongs to the Special Issue MRI in Cancer: Ongoing Developments and Controversies)
Background: Reproducibility and generalization are major challenges for clinically significant prostate cancer modeling using MRI radiomics. Multicenter data seem indispensable to deal with these challenges, but the quality of such studies is currently unknown. The aim of this study was to systematically review the quality of multicenter studies on MRI radiomics for diagnosing clinically significant PCa. Methods: This systematic review followed the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Multicenter studies investigating the value of MRI radiomics for the diagnosis of clinically significant prostate cancer were included. Quality was assessed using the checklist for artificial intelligence in medical imaging (CLAIM) and the radiomics quality score (RQS). CLAIM consisted of 42 equally important items referencing different elements of good practice AI in medical imaging. RQS consisted of 36 points awarded over 16 items related to good practice radiomics. Final CLAIM and RQS scores were percentage-based, allowing for a total quality score consisting of the average of CLAIM and RQS. Results: Four studies were included. The average total CLAIM score was 74.6% and the average RQS was 52.8%. The corresponding average total quality score (CLAIM + RQS) was 63.7%. Conclusions: A very small number of multicenter radiomics PCa classification studies have been performed with the existing studies being of bad or average quality. Good multicenter studies might increase by encouraging preferably prospective data sharing and paying extra care to documentation in regards to reproducibility and clinical utility. View Full-Text
Keywords: radiomics; multicenter MRI; prostate cancer radiomics; multicenter MRI; prostate cancer
Show Figures

Figure 1

MDPI and ACS Style

Bleker, J.; Kwee, T.C.; Yakar, D. Quality of Multicenter Studies Using MRI Radiomics for Diagnosing Clinically Significant Prostate Cancer: A Systematic Review. Life 2022, 12, 946. https://doi.org/10.3390/life12070946

AMA Style

Bleker J, Kwee TC, Yakar D. Quality of Multicenter Studies Using MRI Radiomics for Diagnosing Clinically Significant Prostate Cancer: A Systematic Review. Life. 2022; 12(7):946. https://doi.org/10.3390/life12070946

Chicago/Turabian Style

Bleker, Jeroen, Thomas C. Kwee, and Derya Yakar. 2022. "Quality of Multicenter Studies Using MRI Radiomics for Diagnosing Clinically Significant Prostate Cancer: A Systematic Review" Life 12, no. 7: 946. https://doi.org/10.3390/life12070946

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop